University Medical Center
Welcome,         Profile    Billing    Logout  
 21 Trials 
8 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Stella, Pieter
NCT02661451: Transcatheter Aortic Valve Replacement to UNload the Left Ventricle in Patients With ADvanced Heart Failure (TAVR UNLOAD)

Active, not recruiting
N/A
178
Europe, Canada, US
SAPIEN 3 THV, Optimal Heart Failure Therapy
Cardiovascular Research Foundation, New York, Cardialysis BV, Avania
Aortic Valve Stenosis
02/23
02/25
Boelens, Jaap Jan
BRIDGE, NCT05787574: A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory Condition

Recruiting
2
39
US
Emapalumab, Fludarabine and Dexamethasone, Stem Cell Transplant
Memorial Sloan Kettering Cancer Center, Sobi, Inc.
Primary Immune Regulatory Disorder, Autoimmune Lymphoproliferative, Immune System Diseases
03/27
03/27
NCT04990323: US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies

Recruiting
1/2
12
US
ECT-001-CB (UM171-Expanded Cord Blood Transplant), Conditioning Regimen (Preferred): clofarabine:30 mg/m2/day IV x 4 days, fludarabine:10 mg/m2/day IV x 4 days, busulfan: daily for 4 days with cumm Bu target = 90mg h/L, Conditioning Regimen (Alternative): MIDI: fludarabine: 30 mg/m2/day IV x 5 days, cyclophosphamide: 50 mg/kg IV , thiotepa: 5 mg/kg/day IV x 2 days , TBI: 400 cGy, GVHD Prophylaxis: Tacrolimus/MMF
ExCellThera inc., Memorial Sloan Kettering Cancer Center
High Risk Myeloid Malignancies, Cord Blood Transplant
06/26
06/26
NCT04443907: Study of Safety and Efficacy of Genome-edited Hematopoietic Stem and Progenitor Cells in Sickle Cell Disease (SCD)

Active, not recruiting
1
4
US
OTQ923, Adult Part A, Children 2-17 years old - Part B
Novartis Pharmaceuticals
Sickle Cell Disease
01/25
01/25
NCT05569512: Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AML

Terminated
1
1
US
Uproleselan, Fludarabine, Fludara, Clofarabine, Clolar, Busulfan, Busulfex, Myleran
Malika Kapadia, GlycoMimetics Incorporated
Acute Myeloid Leukemia, Pediatric Cancer
10/23
12/23
Vulpen, Marco van
RIGEL, NCT04304300: Radiotherapy in IDH Mutated Glioma: Evaluation of Late Outcomes

Completed
N/A
80
Europe
Erasmus Medical Center, HollandPTC, Amsterdam University Medical Center, Leiden University Medical Center, Delft University of Technology, Medical Center Haaglanden
Astrocytoma, Grade II, Astrocytoma, Grade III, Oligodendroglioma, Oligodendroglioma, Anaplastic
06/24
06/24
Meine, Mathias
ICONIC-M, NCT05564793: Improving CRT Outcome With Non-Invasive Cardiac Mapping

Recruiting
N/A
330
Europe
Pre-implantation planning, ECGI mapping, Post-implantation assessment
EP Solutions SA
Heart Failure With Reduced Ejection Fraction
09/25
06/26
Checa, Cesar Magro
DRIMID, NCT06285539: Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases

Recruiting
2
60
Europe
Filgotinib
UMC Utrecht, Alfasigma S.p.A., ReumaNederland, Autoimmune Research and Collaboration Hub
Behcet's Disease, Idiopathic Inflammatory Myopathies, IgG4-related Disease
12/26
12/26

Download Options